ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · IEX Real-Time Price · USD
6.49
+0.05 (0.78%)
Apr 26, 2024, 10:45 AM EDT - Market open
ADMA Biologics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ADMA Biologics stock have an average target of 7.88, with a low estimate of 6.00 and a high estimate of 10. The average target predicts an increase of 21.42% from the current stock price of 6.49.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 26, 2024.
Analyst Ratings
The average analyst rating for ADMA Biologics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 → $7.5 | Strong Buy | Reiterates | $6 → $7.5 | +15.56% | Mar 26, 2024 |
| Mizuho | Mizuho | Strong Buy Maintains $9 → $10 | Strong Buy | Maintains | $9 → $10 | +54.08% | Mar 1, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $6.5 → $8 | Buy | Maintains | $6.5 → $8 | +23.27% | Feb 29, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | -7.55% | Feb 29, 2024 |
| Mizuho | Mizuho | Strong Buy Maintains $7 → $9 | Strong Buy | Maintains | $7 → $9 | +38.67% | Jan 22, 2024 |
Financial Forecast
Revenue This Year
340.55M
from 258.22M
Increased by 31.89%
Revenue Next Year
397.67M
from 340.55M
Increased by 16.77%
EPS This Year
0.30
from -0.13
EPS Next Year
0.51
from 0.30
Increased by 68.91%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 353.9M | 415.3M | 475.7M | 444.1M | 484.2M |
| Avg | 340.6M | 397.7M | 440.9M | 406.2M | 431.4M |
| Low | 325.3M | 375.8M | 393.1M | 366.0M | 377.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 37.0% | 21.9% | 19.6% | 0.7% | 19.2% |
| Avg | 31.9% | 16.8% | 10.9% | -7.9% | 6.2% |
| Low | 26.0% | 10.4% | -1.2% | -17.0% | -7.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.34 | 0.54 | 0.71 | 0.54 | 0.58 |
| Avg | 0.30 | 0.51 | 0.60 | 0.52 | 0.56 |
| Low | 0.27 | 0.47 | 0.50 | 0.50 | 0.54 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 76.5% | 39.3% | -11.0% | 11.0% |
| Avg | - | 68.9% | 17.4% | -13.6% | 7.8% |
| Low | - | 55.0% | -2.5% | -16.9% | 3.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.